Overview

A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The primary endpoint of this study is to estimate morphologic complete remission rate. Estimation of response rate is also a secondary objection.
Phase:
Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Treatments:
Azacitidine